The acute-phase response and serum amyloid A inhibit the inflammatory response to Acinetobacter baumannii pneumonia

Journal of Infectious Diseases

Volumn 193, Issue 2, 2006, Pages 187-195

  Renckens, Rosemarijn ^a,b   Roelofs, Joris J T H ^a   Knapp, Sylvia ^a   De Vos, Alex F ^a   Florquin, Sandrine ^a   Van Der Poll, Tom ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; CHEMOKINE; CYTOKINE; SERUM AMYLOID A; SERUM AMYLOID P; TURPENTINE;

ACINETOBACTER BAUMANNII; ACUTE PHASE RESPONSE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GROWTH; BACTERIAL PNEUMONIA; CONTROLLED STUDY; ENZYME ACTIVITY; HISTOPATHOLOGY; HOSPITAL INFECTION; HOST RESISTANCE; INFECTION SENSITIVITY; INFLAMMATION; LUNG LAVAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; SURGICAL PATIENT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ACUTE-PHASE REACTION; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; CHEMOKINES; CROSS INFECTION; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; IRRITANTS; LUNG; MICE; MICE, INBRED C57BL; NEUTROPHIL INFILTRATION; PEROXIDASE; PNEUMONIA, BACTERIAL; PROTEINS; RECOMBINANT PROTEINS; SERUM AMYLOID A PROTEIN; TURPENTINE;

EID: 30944438027     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/498876     Document Type: Article

References (44)

1. Hoffken G, Niederman MS. Nosocomial pneumonia: the importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU. Chest 2002; 122:2183-96.
2. Rello J, Jubert P, Valles J, Artigas A, Rue M, Niederman MS. Evaluation of outcome for intubated patients with pneumonia due to Pseudomonas aeruginosa. Clin Infect Dis 1996; 23:973-8.
3. Heyland DK, Cook DJ, Griffith L, Keenan SP, Brun-Buisson C. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. Am J Respir Crit Care Med 1999; 159:1249-56.
4. Rello J, Rue M, Jubert P, et al. Survival in patients with nosocomial pneumonia: impact of the severity of illness and the etiologic agent. Crit Care Med 1997; 25:1862-7.
5. Rello J, Ausina V, Ricart M, Castella J, Prats G. Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest 1993; 104:1230-5.
6. Chastre J, Trouillet JL. Problem pathogens (Pseudomonas aeruginosa and Acinetobacter). Semin Respir Infect 2000; 15:287-98.
7. Ayan M, Durmaz R, Aktas E, Durmaz B. Bacteriological, clinical and epidemiological characteristics of hospital-acquired Acinetobacter baumannii infection in a teaching hospital. J Hosp Infect 2003; 54:39-45.
8. Zheng H, Fletcher D, Kozak W, et al. Resistance to fever induction and impaired acute-phase response in interleukin-1 beta-deficient mice. Immunity 1995; 3:9-19.
9. Kozak W, Poli V, Soszynski D, Conn CA, Leon LR, Kluger MJ. Sickness behavior in mice deficient in interleukin-6 during turpentine abscess and influenza pneumonitis. Am J Physiol 1997; 272:R621-30.
10. Fantuzzi G, Ku G, Harding MW, et al. Response to local inflammation of IL-1β-converting enzyme-deficient mice. J Immunol 1997; 158:1818-24.
11. Fattori E, Cappelletti M, Costa P, et al. Defective inflammatory response in interleukin 6-deficient mice. J Exp Med 1994; 180:1243-50.
12. Kopf M, Baumann H, Freer G, et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994; 368:339-42.
13. Tilg H, Dinarello CA, Mier JW. IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today 1997; 18:428-32.
14. Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999; 265:501-23.
15. Urieli-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol 2000; 7:64-9.
16. Patel H, Fellowes R, Coade S, Woo P. Human serum amyloid A has cytokine-like properties. Scand J Immunol 1998; 48:410-8.
17. Furlaneto CJ, Campa A. A novel function of serum amyloid A: a potent stimulus for the release of tumor necrosis factor-α, interleukin-1β, and interleukin-8 by human blood neutrophil. Biochem Biophys Res Commun 2000; 268:405-8.
18. Ribeiro FP, Furlaneto CJ, Hatanaka E, et al. mRNA expression and release of interleukin-8 induced by serum amyloid A in neutrophils and monocytes. Mediators Inflamm 2003; 12:173-8.
19. Hatanaka E, Furlaneto CJ, Ribeiro FP, Souza GM, Campa A. Serum amyloid A-induced mRNA expression and release of tumor necrosis factor-alpha (TNF-α) in human neutrophils. Immunol Lett 2004; 91:33-7.
20. Badolato R, Wang JM, Murphy WJ, et al. Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J Exp Med 1994; 180:203-9.
21. Xu L, Badolato R, Murphy WJ, et al. A novel biologic function of serum amyloid A: induction of T lymphocyte migration and adhesion. J Immunol 1995; 155:1184-90.
22. Linke RP, Bock V, Valet G, Rothe G. Inhibition of the oxidative burst response of N-formyl peptide-stimulated neutrophils by serum amyloid-A protein. Biochem Biophys Res Commun 1991; 176:1100-5.
23. Gatt ME, Urieli-Shoval S, Preciado-Patt L, et al. Effect of serum amyloid A on selected in vitro functions of isolated human neutrophils. J Lab Clin Med 1998; 132:414-20.
24. Zimlichman S, Danon A, Nathan I, Mozes G, Shainkin-Kestenbaum R. Serum amyloid A, an acute phase protein, inhibits platelet activation. J Lab Clin Med 1990; 116:180-6.
25. Renckens R, Roelofs JJ, V DEW, et al. The role of plasminogen activator inhibitor type 1 in the inflammatory response to local tissue injury. J Thromb Haemost 2005; 3:1018-25.
26. Knapp S, Wieland CW, van't Veer C, et al. Toll-like receptor 2 plays a role in the early inflammatory response to murine pneumococcal pneumonia but does not contribute to antibacterial defense. J Immunol 2004; 172:3132-8.
27. Rijneveld AW, Weijer S, Florquin S, et al. Thrombomodulin mutant mice with a strongly reduced capacity to generate activated protein C have an unaltered pulmonary immune response to respiratory pathogens and lipopolysaccharide. Blood 2004; 103:1702-9.
28. van Westerloo DJ, Schultz MJ, Bruno MJ, de Vos AF, Florquin S, van der Poll T. Acute pancreatitis in mice impairs bacterial clearance from the lungs, whereas concurrent pneumonia prolongs the course of pancreatitis. Crit Care Med 2004; 32:1997-2001.
29. Bopst M, Haas C, Car B, Eugster HP. The combined inactivation of tumor necrosis factor and interleukin-6 prevents induction of the major acute phase proteins by endotoxin. Eur J Immunol 1998; 28:4130-7.
30. Van Molle W, Hochepied T, Brouckaert P, Libert C. The major acute-phase protein, serum amyloid P component, in mice is not involved in endogenous resistance against tumor necrosis factor alpha-induced lethal hepatitis, shock, and skin necrosis. Infect Immun 2000; 68:5026-9.
31. Lichtman SN, Wang J, Hummel B, Lacey S, Sartor RB. A rat model of ileal pouch-rectal anastomosis. Inflamm Bowel Dis 1998; 4:187-95.
32. Knapp S, Leemans JC, Florquin S, et al. Alveolar macrophages have a protective antiinflammatory role during murine pneumococcal pneumonia. Am J Respir Crit Care Med 2003; 167:171-9.
33. Pantophlet R, Brade L, Brade H. Identification of Acinetobacter baumannii strains with monoclonal antibodies against the O antigens of their lipopolysaccharides. Clin Diagn Lab Immunol 1999; 6:323-9.
34. Leemans JC, Vervoordeldonk MJ, Florquin S, van Kessel KP, van der Poll T. Differential role of interleukin-6 in lung inflammation induced by lipoteichoic acid and peptidoglycan from Staphylococcus aureus. Am J Respir Crit Care Med 2002; 165:1445-50.
35. Strieter RM, Belperio JA, Keane MP. Cytokines in innate host defense in the lung. J Clin Invest 2002; 109:699-705.
36. Zhang P, Summer WR, Bagby GJ, Nelson S. Innate immunity and pulmonary host defense. Immunol Rev 2000; 173:39-51.
37. Munford RS, Pugin J. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med 2001; 163:316-21.
38. Chen GH, Reddy RC, Newstead MW, Tateda K, Kyasapura BL, Standiford TJ. Intrapulmonary TNF gene therapy reverses sepsis-induced suppression of lung antibacterial host defense. J Immunol 2000; 165:6496-503.
39. Shainkin-Kestenbaum R, Berlyne G, Zimlichman S, Sorin HR, Nyska M, Danon A. Acute phase protein, serum amyloid A, inhibits IL-1-and TNF-induced fever and hypothalamic PGE2 in mice. Scand J Immunol 1991; 34:179-83.
40. Laichalk LL, Kunkel SL, Strieter RM, Danforth JM, Bailie MB, Standiford TJ. Tumor necrosis factor mediates lung antibacterial host defense in murine Klebsiella pneumonia. Infect Immun 1996; 64:5211-8.
41. van Westerloo DJ, Knapp S, van't Veer C, et al. Aspiration pneumonitis primes the host for an exaggerated inflammatory response during pneumonia. Crit Care Med 2005; 33:1770-8.
42. 1-acid glycoprotein in nonspecific resistance to a lethal gram-negative infection. J Biol Chem 2000; 275:14903-9.
43. Noursadeghi M, Bickerstaff MC, Herbert J, Moyes D, Cohen J, Pepys MB. Production of granulocyte colony-stimulating factor in the non-specific acute phase response enhances host resistance to bacterial infection. J Immunol 2002; 169:913-9.
44. Alcorn JM, Fierer J, Chojkier M. The acute-phase response protects mice from D-galactosamine sensitization to endotoxin and tumor necrosis factor-alpha. Hepatology 1992; 15:122-9.